Diamyd Medical AB Class B DMYD B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 1.05
- Day Range
- SEK 1.01–1.07
- 52-Week Range
- SEK 0.90–17.46
- Bid/Ask
- SEK 1.02 / SEK 1.03
- Shares Outstanding
- 154.98M
- Market Cap
- SEK 159.63M
- Volume/Avg
- 172,285 / 560,076
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 342.48
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 45
- Website
- https://www.diamyd.com
Valuation
|
Metric
|
DMYD B
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.63 |
Price/Sales | 342.48 |
Price/Cash Flow | — |
Price/Earnings
DMYD B
Financial Strength
|
Metric
|
DMYD B
|
|---|---|
Quick Ratio | 15.49 |
Current Ratio | 15.50 |
Interest Coverage | −177.23 |
Quick Ratio
DMYD B
Profitability
|
Metric
|
DMYD B
|
|---|---|
Return on Assets (Normalized) | −82.68% |
Return on Equity (Normalized) | −112.07% |
Return on Invested Capital (Normalized) | −113.93% |
Return on Assets
DMYD B
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|wjKq%b# | LOCK|f?#J | $123B | |||
| Moderna Inc
MRNA
| LOCK|wK&<v!C | LOCK|<f | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?@@%M$ | LOCK|>!vzZ | $78B | |||
| argenx SE ADR
ARGX
| LOCK|nJbhh< | LOCK|p^> | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|sr?%WgN | LOCK|?! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|cLv@?L | LOCK|kC$?% | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|P$vfF>^ | LOCK|#?xty | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|^fHQHh | LOCK|CDY | $22B | |||
| Incyte Corp
INCY
| LOCK|>%$w#n | LOCK|SM | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@$N>@& | LOCK|&W | $14B |
United States